Drug intelligence / Profile preview

HECN30227

Development stage: Phase 1
Lead developer: Sunshine Lake Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

HECN30227 is a long-acting monoclonal antibody developed by Sunshine Lake Pharma (HEC Pharm) for the treatment of chronic hepatitis B (CHB). It is designed to target and neutralize the hepatitis B surface antigen (HBsAg), thereby reducing the viral load and circulating antigen levels, which may help restore the host's exhausted immune response against the virus. The drug is currently being evaluated in a Phase 1 clinical trial (CTR20254683) to assess its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antiviral activity in both healthy volunteers and patients with chronic hepatitis B.

Targets

ASGPR (Asialoglycoprotein Receptor 1)

Beyond the preview

Go deeper on HECN30227.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HECN30227.

Explore the full profile